Abstract

Glucosamine is commonly used as a nutraceutical by arthritis patients. However, its mode of action is still unknown, and there is controversy about its clinical efficacy. Synthetic N-acyl glucosamines (acyl group > 2 carbons) comprise a new class of drugs. We examined these derivatives for their effect in bone and cartilage cells, and for their ability to serve as acceptor substrates for galactosyltransferase. With the exception of N-benzoylglucosamine, compounds of the series were good substrates for galactosyltransferases from bone and cartilage cells, and for purified enzyme from bovine milk. When N-butyrylglucosamine (GlcNBu) was added to the cell medium of primary bovine chondrocytes and human osteoblasts, small amounts were found to enter the cells and a radiolabeled metabolite appeared in the medium. However, GlcNBu did not appear to be incorporated directly into oligosaccharides. GlcNBu at 1 and 5 mM concentrations in the glucose-free cell medium of primary human osteoblasts from osteoarthritis patients did not significantly alter cell proliferation or cell differentiation.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call